iShares Biotechnology ETF $IBB Holdings Decreased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lowered its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 15.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,528 shares of the financial services provider’s stock after selling 4,186 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in iShares Biotechnology ETF were worth $4,285,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Basepoint Wealth LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth about $26,000. Cary Street Partners Financial LLC bought a new position in shares of iShares Biotechnology ETF in the fourth quarter valued at approximately $29,000. Darwin Wealth Management LLC acquired a new position in shares of iShares Biotechnology ETF during the second quarter valued at approximately $25,000. Caitlin John LLC bought a new stake in iShares Biotechnology ETF during the fourth quarter worth approximately $34,000. Finally, Cornerstone Planning Group LLC bought a new stake in iShares Biotechnology ETF during the fourth quarter worth approximately $35,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

IBB opened at $198.26 on Friday. iShares Biotechnology ETF has a 1-year low of $136.89 and a 1-year high of $201.72. The business has a 50 day moving average price of $186.87 and a two-hundred day moving average price of $176.26.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Monday, June 15th were given a dividend of $0.0238 per share. The ex-dividend date was Monday, June 15th. This represents a $0.10 annualized dividend and a dividend yield of 0.0%.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.